Compare MEG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEG | EVO |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 943.9M | 1.1B |
| IPO Year | 2020 | 2021 |
| Metric | MEG | EVO |
|---|---|---|
| Price | $24.71 | $3.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $33.50 | $7.00 |
| AVG Volume (30 Days) | ★ 338.1K | 250.1K |
| Earning Date | 11-04-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $826,323,000.00 | ★ $887,396,457.00 |
| Revenue This Year | $19.70 | N/A |
| Revenue Next Year | $2.82 | $8.52 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.77 | N/A |
| 52 Week Low | $10.51 | $2.84 |
| 52 Week High | $32.00 | $4.80 |
| Indicator | MEG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 39.77 | 48.75 |
| Support Level | $25.63 | $3.03 |
| Resistance Level | $26.43 | $3.18 |
| Average True Range (ATR) | 0.95 | 0.08 |
| MACD | -0.12 | 0.03 |
| Stochastic Oscillator | 0.68 | 72.58 |
Montrose Environmental Group Inc is an environmental services company. The firm's operating segments are Assessment, Permitting and Response, Measurement and Analysis, and Remediation and Reuse. Through its Assessment, Permitting, and Response segment, the company provides scientific advisory and consulting services to support environmental assessments, environmental emergency response, and environmental audits. Measurement and Analysis include test and analysis of air, water, and soil to determine concentrations of contaminants whereas, the Remediation and Reuse segment provide clients with engineering, design, implementation, operations and maintenance services, to treat contaminated water, remove contaminant or create biogas. United States Contributes the majority of geographic revenue.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.